GlassScriptPhysician profile
Maria I Juarez
NPI 1447297965
$2,291.50
in general payments reported to CMS, 2019-2025
21 companies · $481 in 2025
The $481 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34.23 · 2021: $112 · 2022: $1,091 · 2023: $39.82 · 2024: $533 · 2025: $481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $892 · Education: $162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $892.35 |
| Education | $161.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $928.97 | 2022-2023 | Phesgo |
| Merck Sharp & Dohme LLC | $153.29 | 2025 | Keytruda, Keytruda Qlex |
| Pfizer INC. | $130.79 | 2024-2025 | |
| Monteris Medical Corporation | $124.72 | 2022 | |
| Incyte Corporation | $111.85 | 2024 | Jakafi |
| Sumitomo Pharma America, INC. | $102.42 | 2024 | Orgovyx |
| Glaxosmithkline, LLC. | $102.34 | 2024 | Ojjaara |
| Lilly USA, LLC | $100.39 | 2021 | |
| Ge Healthcare | $96.22 | 2024 | |
| Seagen INC. | $77.97 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $68.02 | 2024-2025 | Opdivo |
| Gilead Sciences, INC. | $62.80 | 2021-2025 | Trodelvy |
| Tempus Ai, INC | $49.97 | 2024-2025 | Xt Cdx |
| Regeneron Healthcare Solutions, INC. | $38.48 | 2022 | |
| Amgen INC. | $28.37 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Caris Mpi, INC. | $25.21 | 2025 | Mi Cancer Seek |
| Astrazeneca Pharmaceuticals LP | $24.23 | 2024 | Imfinzi |
| Janssen Pharmaceuticals, INC | $21.30 | 2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $20.85 | 2023 | |
| Astellas Pharma US INC | $17.45 | 2022 | |
| Clovis Oncology, INC. | $5.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Juarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.